Moreover, in December 2018, Cerus Corporation
announced the initiation and first patient enrollment in a Phase III study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Ltd, Haemonetics Corporation, Fresenius Kabi AG, Kawasumi Laboratories Inc., Cerus Corporation
, NIKKISO CO., LTD., Medica S.p.A., Therakos, Inc.
Biomedical products company Cerus Corporation
(Nasdaq:CERS) announced on Monday its unaudited preliminary product revenue of USD16.5m for the fourth quarter 2018
announced that the American Red Cross has received approval by the U.S.
Biomedical company Cerus Corporation
(Nasdaq:CERS) reported on Tuesday that it has entered into a purchase agreement for the INTERCEPT Blood System for platelets and plasma with The Community Blood Center (CBC).
The first patient has been dosed in Cerus Corporation
's (NASDAQ:CERS) Phase I clinical trial of CRS-100, the company's lead immunotherapy product.
(Nasdaq: MEDI) and Cerus Corporation
(Nasdaq: CERS) have signed an agreement for developing and commercializing a novel therapeutic vaccine designed to treat cancers of the breast, prostate and colon, as well as metastatic melanomas.
, Concord, CA, announced it has initiated a Phase IB clinical trial for its allogeneic cellular immune therapy (ACIT) in collaboration with the National Marrow Donor Program, Minneapolis, MN.
(Nasdaq:CERS), Concord, Calif., has announced results for the third quarter ended September 30, 2001.
(Nasdaq:CERS) and Baxter Healthcare Corporation have submitted a CE Mark application for approval to market the Intercept Platelet System in Europe.
Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation
, Hemacare Corporation, and Medica S.p.A.